Phase 3 Haematological Malignancy Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Haematological MalignancySolid Tumour
Cancer Research UK825 enrolled27 locationsNCT05722886
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaOvarian NeoplasmsColorectal Neoplasms+3 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
Haematological MalignancyHypogammaglobulinemia
Monash University300 enrolled7 locationsNCT05678621